Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Pembrolizumab in Advanced Hepatobiliary Tumors
NCT03895970Phase 2Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and pembrolizumab in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), gallbladder carcinoma and 1 more, sponsored by Peking Union Medical College Hospital. Primary endpoints: Objective Response Rate at 1 year, Disease Control Rate at 1 year and 1 more. Started Apr 2019; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)gallbladder carcinomaampullary carcinoma
Beyond the preview
Go deeper on NCT03895970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895970.